X
Total 959151 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Grid Scaling | Scaling factor that when multiplied by the dose grid data found in Pixel Data (7FE0,0010) attribute of the , yields grid doses in the dose units as specified by Dose Units (3004,0002). | ILX:0103523 | 5 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dose Rate Delivered | Dose Rate actually delivered for segment beginning at current control point (meterset/min). | ILX:0103524 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Rate Set | Dose Rate to be set on treatment machine for segment beginning at current control point (e.g. MU/min). | ILX:0103525 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Reference Description | User-defined description of Dose Reference. | ILX:0103526 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Reference Number | Identification number of the Dose Reference. The value of Dose Reference Number (300A,0012) shall be unique within the RT Plan in which it is created. Required if Dose Reference Sequence (300A,0012) is sent. | ILX:0103527 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Reference Point Coordinates | Coordinates (x,y,z) of Reference Point in the patient based coordinate system described in (mm). | ILX:0103528 | 5 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dose Reference Sequence | Introduces sequence of Dose References. One or more items may be included in this sequence. | ILX:0103529 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Reference Structure Type | Structure type of Dose Reference. | ILX:0103530 | 6 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dose Reference Type | Type of Dose Reference. | ILX:0103531 | 6 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dose Reference UID | A unique identifier for a Dose Reference that can be used to link the same entity across multiple RT Plan objects. | ILX:0103532 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Summation Type | Type of dose summation. | ILX:0103533 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Type | Type of dose. | ILX:0103534 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Units | Dose axis units. | ILX:0103535 | 5 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dose Value | Dose value for ROI, in units defined by Dose Units (3004,0002). Dose Value (3004,0012) shall be the dose value corresponding to the referenced isodose curve, named dose point, or unnamed dose point. | ILX:0103536 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dot pattern expectancy task | No definition submitted yet. | ILX:0103537 | 6 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Doublecortin | A cytoplasmic protein which appears to direct neuronal migration by regulating the organization and stability of microtubules. The encoded protein contains two doublecortin domains, which bind microtubules. In addition, the encoded protein interacts with LIS1, the regulatory gamma subunit of platelet activating factor acetylhydrolase, and this interaction is important to proper microtubule function in the developing cortex (Entrez Gene definition: GeneID: 1641. | ILX:0103538 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Down | A direction from a higher point to a lower point. | ILX:0103539 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Downs syndrome | A disorder caused by the presence of all or part of an extra 21st chromosome, characterized by structural abnormalities throughout the body. Often Down syndrome is associated with some impairment of cognitive ability and physical growth as well as facial appearance. (Adapted from Wikipedia) | ILX:0103540 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Doxacurium chloride | Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration. Pharmacology: Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant. The neuromuscular block produced by doxacurium chloride may be antagonized by anticholinesterase agents. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at reversal, the longer the time and the greater the dose of anticholinesterase required for recovery of neuromuscular function. Doxacurium chloride is approximately 2.5 to 3 times more potent than pancuronium and 10 to 12 times more potent than metocurine. Mechanism of action: Doxacurium chloride binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. Drug type: Approved. Small Molecule. Drug category: Neuromuscular Nondepolarizing Agents | ILX:0103541 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Doxapram | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) Pharmacology: Doxapram is an analeptic agent (a stimulant of the central nervous system). The respiratory stimulant action is manifested by an increase in tidal volume associated with a slight increase in respiratory rate. A pressor response may result following doxapram administration. Provided there is no impairment of cardiac function, the pressor effect is more marked in hypovolemic than in normovolemic states. The pressor response is due to the improved cardiac output rather than peripheral vasoconstriction. Following doxapram administration, an increased release of catecholamines has been noted. Mechanism of action: Doxapram produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. Drug type: Approved. Small Molecule. Drug category: Central Nervous System Stimulants. Respiratory System Agents | ILX:0103542 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
The SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
Contact Us
FAIR Data Informatics Lab
University of California, San Diego
9500 Gilman Drive, Mail Code 0608
La Jolla, CA 92093-0608
United States
info 
scicrunch.org
scicrunch.org
X